Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K
Hybridoma Technology01:31

Hybridoma Technology

13.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.2K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

6.9K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
6.9K
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

110
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Leukemia·2026
Same author

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discovery·2026
Same author

Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma.

Cancer research·2026
Same author

Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancer.

The British journal of dermatology·2026
Same author

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

The New England journal of medicine·2026
Same author

Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10-49 years of age: a population-based study from the National Health and Nutritional Examination Survey.

Blood cancer journal·2026
Same journal

Alcohol-Related Liver Disease: A Review.

JAMA·2026
Same journal

Online Prescribing of GLP-1 Receptor Agonists.

JAMA·2026
Same journal

Using AI Disagreement to Expose Gaps in Coverage Rules.

JAMA·2026
Same journal

Randomized Trials in Pregnancy.

JAMA·2026
Same journal

Randomized Trials in Pregnancy-Reply.

JAMA·2026
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
関連記事をすべて見る

関連する実験動画

Updated: May 2, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K

多発性骨髄腫の前駆性疾患である多発性骨髄腫の病原体である.

Ola Landgren1, Adam Justin Waxman

  • 1National Cancer Institute, National Institutes of Health, Center for Cancer Research, Medical Oncology Branch, 9000 Rockville Pike, Bldg 10/Room 13N240, Bethesda, MD 20892, USA. landgreo@mail.nih.gov

JAMA
|December 2, 2010
PubMed
まとめ
この要約は機械生成です。

多発性骨髄腫は一貫して,未確定意義の単克隆性ガンモパシー (MGUS) や燃える骨髄腫のような前駆体状態に続く. 進行を予測し,これらの初期段階で標的治療を開発するために新しいバイオマーカーが必要です.

さらに関連する動画

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K

関連する実験動画

Last Updated: May 2, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K

科学分野:

  • 血液学 ヘマトロジ
  • 腫瘍学 腫瘍学
  • 分子診断は分子診断です.

背景:

  • 多発性骨髄腫の診断は,臨床的症状 (高カルセミア,腎不全,貧血,骨の損傷) に基づいています.
  • 重要度不明のモノクローナルガンモパシー (MGUS) と燃える骨髄腫 (smoldering myeloma) は,既知の前駆体である.
  • 先駆体状態の現在のリスク分層化は,臨床マーカーを使用しています.

研究 の 目的:

  • 骨髄腫前駆体疾患に関する現在の理解をレビューする.
  • MGUSとスモーリングミエロマのパーソナライズされた管理を改善するためのニーズを特定する.
  • 多発性骨髄腫を予防するための早期治療戦略の開発を検討する.

主な方法:

  • ケースプレゼンテーションと文献レビュー.
  • 現在の診断基準とリスク分層化ツールの分析.
  • 分子メカニズムと潜在的な治療標的の議論.

主要な成果:

  • 多発性骨髄腫は一貫してMGUSと燃える骨髄腫に続く.
  • 高リスク前駆体識別のためのバイオマーカーと分子イメージングにおいて,重要なギャップが存在します.
  • 現在の方法は,変換メカニズムを完全に解明したり,標的治療を導くことができません.

結論:

  • 骨髄腫前駆体状態の新しいバイオマーカーとイメージング技術に対する重大な需要があります.
  • パーソナライズされた管理と早期介入戦略は,多発性骨髄腫の予防に不可欠です.
  • 分子経路に関するさらなる研究は,標的治療の開発を容易にすることができます.